Editorial Comment to Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
- 20 June 2016
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 23 (8) , 666
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinicInternational Journal of Urology, 2016
- ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerExpert Review of Anticancer Therapy, 2015
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen ReceptorClinical Cancer Research, 2014
- An androgen receptor N-terminal domain antagonist for treating prostate cancerJournal of Clinical Investigation, 2013
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen ReceptorCancer Cell, 2010